Bioventus Inc.
BVS
$8.16
-$0.99-10.82%
| 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 96.77% | 79.89% | -424.99% | 25.03% | 16.53% |
| Total Depreciation and Amortization | -246.75% | -6.23% | 11.07% | 165.19% | -230.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 923.83% | -83.81% | 1,235.13% | -94.06% | 1,783.41% |
| Change in Net Operating Assets | -360.26% | -108.26% | 137.56% | -847.19% | 112.18% |
| Cash from Operations | 87.30% | -31.96% | 352.49% | -157.89% | 224.76% |
| Capital Expenditure | -796.88% | 16.88% | 73.54% | 21.14% | 81.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Investing | 37,762.50% | 16.88% | 92.30% | -69.20% | 70.97% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | 100.00% | -170.42% | -- | 100.00% |
| Issuance of Common Stock | 99.46% | -9.20% | 244.07% | 12.03% | -60.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2,354.45% | -0.53% | 86.06% | -692.44% | -2.38% |
| Cash from Financing | -11,938.40% | 104.61% | -84.94% | -30,200.00% | -100.17% |
| Foreign Exchange rate Adjustments | -542.70% | 211.22% | 22.98% | -247.83% | 183.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.47% | 62.44% | 157.85% | -216.32% | 495.67% |
